MoonLake Immunotherapeutics saw its stock climb sharply in morning trading following the publication of its Week 52 Phase 3 readout for sonelokimab and an Investor Day webcast held the next morning. The shares rose 8.6% in early trading as investors digested the long-term efficacy numbers and the company’s regulatory timeline.
Clinical results at one year
Pooling results from the VELA-1 and VELA-2 studies, MoonLake reported that 67.2% of patients treated with sonelokimab reached HiSCR75 at the one-year point. The dataset also showed that 33.1% of treated patients achieved HiSCR100, while 26.0% attained full inflammatory remission. The company stated that no new safety signals were detected in the combined analysis.
In a separate but related readout, interim Week 24 data from the VELA-TEEN adolescent trial indicated that roughly 68% of adolescent participants achieved HiSCR75. MoonLake noted that these pediatric results open the door to a potential label covering patients as young as 12.
Regulatory pathway and timeline
MoonLake confirmed it intends to submit a Biologics License Application to the U.S. Food and Drug Administration by the end of September 2026. The company also indicated it expects a Prescription Drug User Fee Act (PDUFA) action date by late November 2026. Management said it plans to request Priority Review, which the company estimates could shorten time-to-market by roughly one quarter.
Market and peer context
Analyst commentary provided an additional backdrop to the market reaction. H.C. Wainwright maintains a Buy rating with a $45 price target on the equity, while Needham recently lifted its target to $30. MoonLake’s presentation further positioned its VELA results against approved IL-17 inhibitors marketed by Novartis and UCB, asserting a meaningful efficacy advantage at the one-year mark versus those comparators.
Macro conditions offered limited support for the stock move. The S&P 500 was up about 0.2% and the NASDAQ was down roughly 0.1%, suggesting MoonLake’s upward move was driven by company-specific developments rather than broader market momentum.
Share movement and investor reaction
The convergence of robust one-year efficacy data, a clean safety profile, encouraging adolescent results, a clear BLA submission timetable, and a live Investor Day presentation produced concentrated positive sentiment. Shares reached an intraday high of $21.20 and later traded at $20.64, well above the prior close of $19.21.
What this means
The combined clinical data and regulatory timeline supplied investors with a clearer view of the near-term path for sonelokimab. The adolescent data in particular could expand the addressable population if regulators accept a pediatric indication, while the company’s stated intent to seek Priority Review could accelerate market access by an estimated quarter.